This research study is being conducted to determine if taking oral (by mouth in pill form) Apatone®B (a combination of Vitamins C and K3) will reduce chronic joint discomfort and improve function of non-infected symptomatic postoperative total joint replacements.

To perform a prospective, randomized, double-blind clinical trial to determine if oral Apatone®B, an amalgam of vitamins C and K3, has a therapeutic efficacy beyond the conservative care customarily used to reduce inflammatory synovitis and to increase the functional capacity of proven non-infected symptomatic postoperative total joint replacements.

Inclusion Criteria:

• Postoperative Total joint replacement with osteoarthritis as the underlying pathology
• Proven non-infected symptomatic Total Joint Arthroplasty (TJA) (joint implanted for >12 months post-op)
• Age (50 to 85 years of age); based on a 10% trim of the age distribution for Summa Health System TJAs (7/1/08-6/30/2009).

Exclusion Criteria:

• An infection of any kind (prior to, or during the study)
• Rheumatoid arthritis as the underlying pathology
• Cortisone injection received <6 months prior to study enrollment
• Insulin dependent diabetes
• Diagnosed immunodeficiency
• On dialysis or have poor kidney function
• Anti-coagulant medication (e.g., Coumadin or >100mg of Aspirin daily)
• Anti-seizure medication (e.g., Dilantin)
• Steroidal medication (e.g., Prednisone, Advair or Symbicort)
• NSAIDS (e.g., Celebrex or Toradol); a 14-day washout period will be allowed
• bisphosphonates (e.g., Fosamax, Actonel, Aredia, Didronel, Boniva or Reclast)
• hormonal therapy (e.g., Estrogen, Progesterone or Testosterone)
• Cancer (active or in remission)
• Planned concurrent vitamins exceeding a standard daily multivitamin or exceeding the Recommended Daily Allowance (RDA) for individual vitamins if used alone; a 72 hour wash out period will be allowed
• A glucose-6-phosphate dehydrogenase (G6PD) deficiency
• Pregnant or lactating; females who are in their reproductive years must have a negative serum pregnancy
• Lactose intolerant
• Citric acid intolerant

All adverse events (AEs) were classified by the investigator with respect to severity (mild, moderate, severe and potentially life threatening). No AEs classified as potentially life threatening were reported during the course of this study, nor were there any deaths.

limited accrual due to meeting stringent study inclusion/exclusion criteria.Stringent inclusion/exclusion created to allow SEB analyses w/o interference or artifacts,& not due to study drug issues,interaction or limitations.